✦ LIBER ✦

806 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small-cell lung cancer who are > 69 years of age or who have performance status (PS) = 2

✍ Scribed by D. Bodkin; M. Neubauer; M.G. Bolton

Book ID: 118620972
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 170 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90831-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-140 Phase 2 study of first line chemot

O-140 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX™) in patients with non-small-cell lung cancer who are ≥ 70 years of age or performance status (PS) = 2

✍ Bodkin, David; Neubauer, Marcus; Bolton, Mary G. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Phase II Study of first-line chemotherap

Phase II Study of first-line chemotherapy using CT-2103 in patients with Non-Small-Cell Lung Cancer who are > or = 70 years of age or who have PS = 2

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Phase 2 trial of docetaxel and gefitinib

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

✍ George R. Simon; Martine Extermann; Alberto Chiappori; Charles C. Williams; Mube 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

## Abstract ## BACKGROUND This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progress

O7 An exploratory analysis of the impact

O7 An exploratory analysis of the impact of age, performance status, and comorbidity on clinical outcomes in a randomized phase II trial of single agent gemcitabine, vinorelbine or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly

✍ Ngeow, J.; Poon, D.; Leong, S.S.; Gao, F.; Toh, C.K.; Lim, W.T.; Xu, L.; Tan, S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

2LB Phase III, randomized, open-label, p

2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST)

✍ J.Y. Douillard; E.S. Kim; V. Hirsh; T. Mok; M. Socinski; R. Gervais; L.Y. Wu; L. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 39 KB